Insider Transactions in Q4 2024 at Aura Biosciences, Inc. (AURA)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2024
|
Janet Jill Hopkins Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,822
-7.23%
|
$106,398
$9.36 P/Share
|
|
Oct 29
2024
|
Pinos Elisabet De Los |
SELL
Open market or private sale
|
Direct |
9,200
-2.79%
|
$92,000
$10.74 P/Share
|
|
Oct 29
2024
|
Amy Elazzouzi Vice President, Finance |
SELL
Open market or private sale
|
Direct |
553
-1.38%
|
$5,530
$10.74 P/Share
|
|
Oct 18
2024
|
Julie B Feder Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,131
-15.77%
|
$301,572
$12.03 P/Share
|
|
Oct 18
2024
|
Julie B Feder Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,131
+5.02%
|
$100,524
$4.16 P/Share
|
|
Oct 18
2024
|
Pinos Elisabet De Los |
SELL
Open market or private sale
|
Direct |
24,992
-7.04%
|
$299,904
$12.04 P/Share
|
|
Oct 18
2024
|
Pinos Elisabet De Los |
BUY
Exercise of conversion of derivative security
|
Direct |
24,992
+6.58%
|
$49,984
$2.74 P/Share
|
|
Oct 16
2024
|
Mark Plavsic Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
7,383
-5.74%
|
$66,447
$9.85 P/Share
|